Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The company's approved products include Paclical/Apealea, a water-soluble formulation of XR17 and paclitaxel to treat cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops Doxophos, a formulation of XR17 and doxorubicin to treat cancer comprising leukaemia, breast cancer, and lymphoma; Docecal, a formulation of XR17 and docetaxel for the treatment of prostate, lung, and breast cancer; OAS-19, a cancer drug; and KB9520 to treat various types of cancer. The company also develops Doxophos Vet, a formulation to treat lymphoma in dogs. Oasmia Pharmaceutical AB (publ) was founded in 1990 and is based in Uppsala, Sweden.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone461-850-5440
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$380,000.00
Profitability
Miscellaneous
Employees58
OptionableNot Optionable
OASMIA PHARMACE/ADR (NASDAQ:OASM) Frequently Asked Questions
What is OASMIA PHARMACE/ADR's stock symbol?
OASMIA PHARMACE/ADR trades on the NASDAQ under the ticker symbol "OASM."
How were OASMIA PHARMACE/ADR's earnings last quarter?
OASMIA PHARMACE/ADR (NASDAQ:OASM) posted its quarterly earnings results on Friday, November, 30th. The company reported ($0.11) EPS for the quarter. The company earned $0.02 million during the quarter. OASMIA PHARMACE/ADR had a negative return on equity of 42.63% and a negative net margin of 8,328.50%. View OASMIA PHARMACE/ADR's Earnings History.
When is OASMIA PHARMACE/ADR's next earnings date?
Has OASMIA PHARMACE/ADR been receiving favorable news coverage?
News headlines about OASM stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OASMIA PHARMACE/ADR earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of OASMIA PHARMACE/ADR's key competitors?
Some companies that are related to OASMIA PHARMACE/ADR include Arvinas (ARVN), Flexion Therapeutics (FLXN), NuCana (NCNA), Zymeworks (ZYME), Obseva (OBSV), Theratechnologies (THERF), BioSpecifics Technologies (BSTC), Prothena (PRTA), Forty Seven (FTSV), Innate Pharma (IPHYF), Odonate Therapeutics (ODT), Corium International (CORI), GlycoMimetics (GLYC), Arcus Biosciences (RCUS) and Eidos Therapeutics (EIDX).
Who are OASMIA PHARMACE/ADR's key executives?
OASMIA PHARMACE/ADR's management team includes the folowing people:
- Mr. Julian Aleksov, Co-Founder & Exec. Chairman (Age 54)
- Mr. Mikael Asp, CEO & Head of Quality Assurance (Age 57)
- Mr. Anders Blom, CFO & Exec. VP (Age 50)
- Ms. Och Annette Ljungmark, Head of Accounting and HR (Age 69)
- Mr. John T. Cosby, Head of Regulatory Affairs (Age 57)
How do I buy shares of OASMIA PHARMACE/ADR?
Shares of OASM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OASMIA PHARMACE/ADR's stock price today?
One share of OASM stock can currently be purchased for approximately $3.1158.
How big of a company is OASMIA PHARMACE/ADR?
OASMIA PHARMACE/ADR has a market capitalization of $131.98 million and generates $380,000.00 in revenue each year. OASMIA PHARMACE/ADR employs 58 workers across the globe.
What is OASMIA PHARMACE/ADR's official website?
How can I contact OASMIA PHARMACE/ADR?
OASMIA PHARMACE/ADR's mailing address is VALLONGATAN 1, UPPSALA V7, 75228. The company can be reached via phone at 461-850-5440 or via email at [email protected]
MarketBeat Community Rating for OASMIA PHARMACE/ADR (NASDAQ OASM)
MarketBeat's community ratings are surveys of what our community members think about OASMIA PHARMACE/ADR and other stocks. Vote "Outperform" if you believe OASM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OASM will underperform the S&P 500 over the long term. You may vote once every thirty days.
